- $2.41bn
- $1.15bn
- $630.20m
- 50
- 67
- 31
- 47
REG - Hutchmed China Ltd - Total Voting Rights
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Highlights Data at ESMO and ASH
AnnouncementRCS - Hutchmed China Ltd - Enrollment Complete in SAFFRON Global Phase III
AnnouncementRCS - Hutchmed China Ltd - Updates from R&D Event
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Presents Data at AACR NCI EORTC
AnnouncementREG - Hutchmed China Ltd - Vesting of awards under Long Term Incentive Plan
AnnouncementREG - Hutchmed China Ltd - Appointment of Independent Non-executive Director
AnnouncementRCS - Hutchmed China Ltd - Data to be Presented at the 2025 ESMO Congress
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Highlights Data to be Presented at ESMO
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED to Present R&D Updates on October 31 2025
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Highlights Data to be Presented at CSCO
AnnouncementREG - Hutchmed China Ltd - Directorate Change
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Completes Enrollment of Phase III Trial
AnnouncementREG - Hutchmed China Ltd - 2025 Interim Results
AnnouncementREG - Hutchmed China Ltd - HUTCHMED to Announce 2025 Half-Year Results
AnnouncementREG - Hutchmed China Ltd - Update on Joint Corporate Brokers in London
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementREG - Hutchmed China Ltd - China Approval based on Phase III SACHI Trial
Announcement